Comment on: “The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome”

Thrombosis Research

Volumn 157, Issue , 2017, Pages 82-83

  Yazici, Ayten ^a   Unlu, Ozan ^b,c   Erkan, Doruk ^b,c  

^a KOCAELI UNIVERSITY   (Turkey)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PHOSPHOLIPID ANTIBODY;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CARDIOVASCULAR RISK; CLINICAL OUTCOME; DRUG EFFICACY; HUMAN; LETTER; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); THROMBOSIS; TREATMENT OUTCOME; VEIN THROMBOSIS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FACTOR XA INHIBITORS; HUMANS;

EID: 85023635819     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2017.07.010     Document Type: Letter

References (10)

1. Malec, K., Goralczyk, T., Undas, A., The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. Thromb. Res. 152 (2017), 93–97.
2. Yazici, A., Unlu, O., Erkan, D., A systematic review of direct oral anticoagulant use in antiphospholipid syndrome [abstract]. Arthritis Rheum. 68:Suppl. 10 (2016), 92–93.
3. Cervera, R., Serrano, R., Pons-Estel, G.J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramon, E., et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 74 (2015), 1011–1018.
4. Unlu, O., Branch, W.D., Fortin, P.R., Gerosa, M., Pons-Estel, G.J., Tektonidou, M., et al. Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry analysis: first and recurrent thrombosis risk after 720 patient-years of follow-up[abstract]. Arthritis Rheum. 68:Suppl. 10 (2016), 73–74.
5. Erkan, D., Aguiar, C.L., Andrade, D., Cohen, H., Cuadrado, M.J., Danowski, A., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun. Rev. 13 (2014), 685–696.
6. Cohen, H., Hunt, B.J., Efthymiou, M., Arachchillage, D.R., Mackie, I.J., Clawson, S., et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 3 (2016), e426–e436.
7. Rivaroxaban for Antiphospholipid Antibody Syndrome (RAPS), Available from: https://clinicaltrials.gov/ct2/show/NCT02116036, 2017.
8. Pengo, V., Banzato, A., Bison, E., Zoppellaro, G., Padayattil Jose, S., Denas, G., Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 25 (2016), 301–306.
9. Woller, S.C., Stevens, S.M., Kaplan, D.A., Branch, D.W., Aston, V.T., Wilson, E.L., et al. Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome: study rationale and design (ASTRO-APS). Clin. Appl. Thromb. Hemost. 22 (2016), 239–247.
10. Andrade, D., Cervera, R., Cohen, H., Crowther, M., Cuadrado, M.J., et al. Erkan, D., Lockshin, M.D., (eds.) 15th International Congress on aPL Task Force Report on APS Treatment Trends Report Antiphospholipid Syndrome – Current Research Highlights and Clinical Insights, 2017, Springer, 317–338.